Suppr超能文献

全身 MRI 指导下受累隔室照射联合大剂量化疗和干细胞解救可提高多发性骨转移尤文氏瘤患者的长期生存。

Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases.

机构信息

Department of Pediatrics, Technische Universität München, and Pediatric Oncology Center, Munich, Germany.

出版信息

Bone Marrow Transplant. 2010 Mar;45(3):483-9. doi: 10.1038/bmt.2009.184. Epub 2009 Aug 17.

Abstract

We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: P<0.005). We conclude that TB-MRI-governed ICI followed by HDC and SCR in ET-MBM is feasible and warrants further evaluation in prospective studies.

摘要

我们研究了全身磁共振成像(TB-MRI)指导下受累部位照射(ICI)和大剂量化疗(HDC),继以干细胞解救(SCR)在伴多发骨转移的高危尤文氏肿瘤(ET)患者(高风险 ET-MBM)中的作用。1995 年至 2000 年,11 例高风险 ET-MBM 患者经 TB-MRI 初始评估受累骨骼,入组本研究(A 组)。11 例患者中,6 例初诊时即有肺部疾病;所有患者均有多发性骨病变,累及 3 个以上骨骼。全身诱导治疗采用依托泊苷、长春新碱、阿霉素(多柔比星)、异环磷酰胺和放线菌素 D(EVAIA)或 VAIA 化疗,TB-MRI 阳性的所有部位均行 ICI,继以 HDC 和 SCR。选择同期入组的 26 例诊断时累及 3 个以上骨骼的患者,采用欧洲协作组尤文肉瘤研究-92(EICESS-92)方案(B 组)作为对照。这些患者未行 TB-MRI,未行 TB-MRI 指导的 ICI、HDC 和 SCR。A 组与 B 组患者的 5 年生存率分别为 45%和 8%,10 年生存率分别为 27%和 8%(log-rank 和 Breslow:P<0.005)。我们的结论是,TB-MRI 指导下的 ICI 继以 HDC 和 SCR 用于 ET-MBM 是可行的,值得进一步前瞻性研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验